Vacunas antineumocócicas. Nuevas vacunas conjugadas para el adulto

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)


© 2015 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Pneumococcal infections are a significant cause of morbidity and mortality, and are one of the 10 leading causes of death worldwide. Children under 2 years have a higher incidence rate, followed by adults over 64 years. The main risk group are individuals with immunodeficiency, and those with anatomical or functional asplenia, but can also affect immunocompetent persons with certain chronic diseases. Significant progress has been made in the last 10 years in the prevention of these infections. Until a few years ago, only the 23-valent non-conjugate pneumococcal vaccine was available. Its results were controversial in terms of efficacy and effectiveness, and with serious limitations on the type of immune response induced. The current possibility of using the 13-valent conjugate vaccine in adults has led to greater expectations in improving the prevention of pneumococcal disease in these age groups.
Original languageEnglish
Pages (from-to)617-624
JournalEnfermedades Infecciosas y Microbiologia Clinica
Issue number9
Publication statusPublished - 1 Jan 2015


  • Adults
  • Pneumococcal vaccines
  • Streptococcus pneumoniae

Fingerprint Dive into the research topics of 'Vacunas antineumocócicas. Nuevas vacunas conjugadas para el adulto'. Together they form a unique fingerprint.

Cite this